In vitro and in vivo effects of Galectin‐3 inhibitor TD139 on inflammation and ERK/JNK/p38 pathway in gestational diabetes mellitus
Authors:
Open Access
- 4 September 2024
- journal article
- research article
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- Vol. 40 (10) , 916-925
Abstract
This study aims to investigate the effects of the Galectin‐3 (Gal‐3) inhibitor TD139 on inflammation and the extracellular signal‐regulated kinase (ERK)/c‐Jun N‐terminal kinase (JNK)/p38 pathway in gestational diabetes mellitus (GDM). Human placental tissues were treated with TD139 and TNF‐α, assessing Gal‐3, ERK/JNK/p38 activation, and inflammatory cytokines. GDM was induced in mice via subcutaneous injections of streptozotocin (STZ). After confirming GDM, mice were treated with 15 mg/kg TD139 on GD 10.5 12.5, 14.5, 16.5, and 18.5. Serum inflammatory cytokines were measured on GD 20.5, and post‐delivery placental tissues were analyzed. Data were analyzed using one‐way or two‐way repeated measures ANOVA with post hoc tests. TD139 suppressed TNF‐α‐induced increases in Gal‐3, IL‐1β, IL‐6, MCP‐1, and ERK/JNK/p38 activation in placental tissues. In STZ‐induced GDM mice, TD139 reduced glucose levels, weight loss, and food and water intake. TD139 significantly lowered TNF‐α, IL‐1β, IL‐6, and MCP‐1 in serum and placental tissues and inhibited the ERK/JNK/p38 pathway. TD139 improved pup numbers in GDM mice compared to untreated ones. TD139 reduces inflammation and inhibits the ERK/JNK/p38 pathway in TNF‐α stimulated placental tissues and STZ‐induced GDM mice, suggesting its therapeutic potential for managing GDM‐related placental inflammation and improving pregnancy outcomes. The study used TNF‐α to mimic GDM in placental tissues and an STZ‐induced GDM mouse model, which may not fully represent human GDM complexity. Future research should explore alternative models, and broader signaling pathways, and thoroughly evaluate TD139's safety in pregnancy.Keywords
This publication has 39 references indexed in Scilit:
- Healing the diabetic wound: Unlocking the secrets of genes and pathwaysEuropean Journal of Pharmacology, 2024
- Galectin-3 modulates microglial activation and neuroinflammation in early brain injury after subarachnoid hemorrhageExperimental Neurology, 2024
- Effect of galectin-3 on synovial inflammation in knee osteoarthritis via stimulating phosphatidylinositol-3-kinase/Akt pathwayInternational Immunopharmacology, 2023
- Galectin-3 regulates microglial activation and promotes inflammation through TLR4/MyD88/NF-kB in experimental autoimmune uveitisClinical Immunology, 2022
- Emerging roles of Galectin-3 in diabetes and diabetes complications: A snapshotReviews in Endocrine and Metabolic Disorders, 2022
- Galectin-3 knock down inhibits cardiac ischemia-reperfusion injury through interacting with bcl-2 and modulating cell apoptosisArchives of Biochemistry and Biophysics, 2020
- Galectin-3 regulates UVB-induced inflammation in skinJournal of Dermatological Science, 2020
- Gal‐3 regulates the capacity of dendritic cells to promote NKT‐cell‐induced liver injuryEuropean Journal of Immunology, 2014
- Serum galectin-3 levels in women with PCOSJournal of Endocrinological Investigation, 2014
- Galectin‐3 deficiency protects pancreatic islet cells from cytokine‐triggered apoptosis in vitroJournal of Cellular Physiology, 2012